Osteonecrosis of the jaw after zoledronic acid and denosumab treatment

Journal of Clinical Oncology

Volumn 29, Issue 17, 2011, Pages

  Fusco, Vittorio ^a   Galassi, Claudia ^b   Berruti, Alfredo ^c,d   Ciuffreda, Libero ^b   Ortega, Cinzia ^e   Ciccone, Giovannino ^b   Angeli, Alberto ^d   Bertetto, Oscar ^f  

^a C Arrigo Children's Hospital   (Italy)

^b MOLINETTE HOSPITAL   (Italy)

^c SAN LUIGI GONZAGA UNIVERSITY HOSPITAL   (Italy)

^d UNIVERSITY OF TURIN   (Italy)

^e Istituto Per la Ricerca Contro il Cancro   (Italy)

^f Coordinamento Rete Oncologica di Piemonte e Valle d'Aosta ^*  (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DENOSUMAB; ZOLEDRONIC ACID;

BONE METASTASIS; BREAST CARCINOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; HUMAN; ITALY; JAW OSTEONECROSIS; LETTER; MORBIDITY; PATIENT PARTICIPATION; PRIORITY JOURNAL; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL (TOPIC); TOOTH EXTRACTION; TREATMENT DURATION; UNITED STATES;

ANTIBODIES, MONOCLONAL; BONE DENSITY CONSERVATION AGENTS; BONE NEOPLASMS; DIPHOSPHONATES; HUMANS; IMIDAZOLES; INCIDENCE; JAW DISEASES; OSTEONECROSIS; RANK LIGAND;

EID: 79959198190     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.35.1551     Document Type: Letter

References (18)

1. Migliorati CA, Epstein JB, Abt E, et al: Osteonecrosis of the jaw and bisphosphonates in cancer: A narrative review. Nat Rev Endocrinol 7:34-42, 2011
2. Vescovi P, Campisi G, Fusco V, et al: Surgery-triggered and non surgery-triggered Bisphosphonate-Related Osteonecrosis of the Jaws (BRONJ): A retrospective analysis of 567 cases in an Italian multicenter study. Oral Oncol 47:191-194, 2011
3. Ruggiero SL: Bisphosphonate-related osteonecrosis of the jaw (BRONJ): Initial discovery and subsequent development. J Oral Maxillofac Surg 67:13-18, 2009 (suppl 5)
4. Edwards BJ, Gounder M, McKoy JM, et al: Pharmacovigilance and reporting oversight in US FDA fast-track process: Bisphosphonates and osteonecrosis of the jaw. Lancet Oncol 9:1166-1172, 2008
5. Fedele S, Porter SR, D'Aiuto F, et al: Nonexposed variant of bisphosphonate-associated osteonecrosis of the jaw: A case series. Am J Med 123:1060-1064, 2010
6. Ruggiero SL, Dodson TB, Assael LA, et al: American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws: 2009 update. J Oral Maxillofac Surg 67:2-12, 2009 (suppl 5)
7. Ruggiero S, Gralow J, Marx RE, et al: Practical guidelines for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in patients with cancer. J Oncol Pract 2:7-14, 2006
8. Weitzman R, Sauter N, Eriksen EF, et al: Critical review: Updated recommendations for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in cancer patients-May 2006. Crit Rev Oncol Hematol 62:148-152, 2007
9. Advisory Task Force on Bisphosphonate-Related Osteonecrosis of the Jaws, American Association of Oral and Maxillofacial Surgeons: American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg 65:369-376, 2007
10. Ripamonti CI, Maniezzo M, Campa T, et al: Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates: The experience of the National Cancer Institute of Milan. Ann Oncol 20:137-145, 2009
11. Dimopoulos MA, Kastritis E, Bamia C, et al: Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid. Ann Oncol 20:117-120, 2009
12. Fornier MN: Denosumab: Second chapter in controlling bone metastases or a new book? J Clin Oncol 28:5127-5131, 2010
13. Rajkumar SV: Zoledronic acid in myeloma: MRC Myeloma IX. Lancet 376:1965-1966, 2010
14. Stopeck AT, Lipton A, Body JJ, et al: Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: A randomized, double-blind study. J Clin Oncol 28:5132-5139, 2010
15. Henry D, Von Moos R, Vadhan-Raj S, et al: A double-blind, randomized study of denosumab versus zoledronic acid for the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. Presented at the European Cancer Organisation 15 - European Society for Medical Oncology 34 European Multidisciplinary Congress, Berlin, Germany, September 20-24, 2009
16. Fizazi K, Carducci MA, Smith MR, et al: A randomized phase III trial of denosumab versus zoledronic acid in patients with bone metastases from castration-resistant prostate cancer. J Clin Oncol 28:343s, 2010 (suppl; abstr LBA4507)
17. Fusco V, Loidoris A, Colella G, et al: Osteonecrosis of the jaw (ONJ) risk in breast cancer patients after zoledronic acid treatment. Breast 19:432-433, 2010
18. rd Annual San Antonio Breast Cancer Symposium, San Antonio, TX, December 8-12, 2010